NCT00961844

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Phase I/II Trial for Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Steinar Aamdal · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell expansion after lymphodepletion for the patients who show an immune response.

Conditions

• Metastatic Malignant Melanoma

Interventions

Type	Name	Description
BIOLOGICAL	Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion
DRUG	Temozolomide

Timeline

• Start date: 2009-08-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2009-08-19
• Last updated: 2021-02-26

Locations

1 site across 1 country: Norway